TY  - GEN
AU  - Delea,Thomas E
AU  - Zhang,Xinke
AU  - Amdahl,Jordan
AU  - Boyko,Diana
AU  - Dirnberger,Franziska
AU  - Campioni,Marco
AU  - Cong,Ze
TI  - Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States
SN  - 1179-2027
PY  - 2020///0625
KW  - Adult
KW  - Antibodies, Bispecific
KW  - administration & dosage
KW  - Antineoplastic Agents
KW  - Cost-Benefit Analysis
KW  - Disease-Free Survival
KW  - Female
KW  - Humans
KW  - Inotuzumab Ozogamicin
KW  - Male
KW  - Middle Aged
KW  - Models, Economic
KW  - Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
KW  - drug therapy
KW  - Quality-Adjusted Life Years
KW  - Randomized Controlled Trials as Topic
KW  - United States
N1  - Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1007/s40273-019-00812-6
ER  -